S&P 500: 669.03 +1.0% NASDAQ 100: 600.38 +1.1% Dow Jones: 470.30 +0.8%

Paul Tudor Jones’s VANI Holdings & Trades

First Buy
Q4 2025
Duration Held
1 Quarters
Largest Add
Q4 2025
+916,362 Shares
Current Position
916,362 Shares
$1.13 M Value

Paul Tudor Jones's VANI Position Overview

Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 916,362 shares of Vivani Medical, Inc. (VANI) worth $1.13 M, representing 0.00% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Paul Tudor Jones has initiated a new position in VANI, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Paul Tudor Jones's Vivani Medical (VANI) Holding Value Over Time

Track share changes against reported price movement

Quarterly Vivani Medical (VANI) Trades by Paul Tudor Jones

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 +916,362 New Buy 916,362 $1.23

Paul Tudor Jones's Vivani Medical Investment FAQs

Paul Tudor Jones first purchased Vivani Medical, Inc. (VANI) in Q4 2025, acquiring 916,362 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Paul Tudor Jones has held Vivani Medical, Inc. (VANI) for 1 quarters since Q4 2025.

Paul Tudor Jones's largest addition to Vivani Medical, Inc. (VANI) was in Q4 2025, adding 916,362 shares worth $1.13 M.

According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 916,362 shares of Vivani Medical, Inc. (VANI), valued at approximately $1.13 M.

As of the Q4 2025 filing, Vivani Medical, Inc. (VANI) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.

Paul Tudor Jones's peak holding in Vivani Medical, Inc. (VANI) was 916,362 shares, as reported at the end of Q4 2025.